Heyrman Bert, Meers Stef, De Becker Ann, Wouters Kristien, Van Hoof Achiel, Van De Velde Ann, Graux Carlos, Mazure Dominiek, Selleslag Dominik, Maes Helena, Lemmens Jan, Beckers Marielle, Breems Dimitri, Sid Sélim, Berneman Zwi, Anguille Sébastien
Ziekenhuis Netwerk Antwerpen, Department of Haematology, 2020 Antwerp, Belgium.
Algemeen Ziekenhuis KLINA, Department of Haematology, 2930 Brasschaat, Belgium.
Cancers (Basel). 2023 Jun 22;15(13):3296. doi: 10.3390/cancers15133296.
Patients with myelodysplastic syndromes suffer from an impaired quality of life that is only partially explained by physical symptoms. In an observational study, we aimed to investigate the impact of current MDS treatments and the influence of disease perception on quality of life. Serial measurement of health-related quality of life was performed by 'the QUALMS', a validated MDS-specific patient reported outcome tool. Disease perception was evaluated by means of the Brief Illness Perception Questionnaire (B-IPQ). We prospectively collected data on 75 patients that started on a new treatment and could not demonstrate a significant change in QUALMS score or B-IPQ score during treatment. Six out of eight items evaluated in the B-IPQ correlated significantly with QUALMS score. In this small sample, no significant difference in QUALMS score was found between lower vs. higher risk MDS patients or other studied variables, e.g., targeted hemoglobin showed no correlation with QUALMS score. In daily practice attention must be paid to initial formation of disease perception as it correlates independently with health-related quality of life and does not change during treatment (clinicaltrials.gov identifier: NCT04053933).
骨髓增生异常综合征患者的生活质量受损,而身体症状只能部分解释这种情况。在一项观察性研究中,我们旨在调查当前骨髓增生异常综合征治疗的影响以及疾病认知对生活质量的影响。通过“QUALMS”对健康相关生活质量进行系列测量,“QUALMS”是一种经过验证的、特定于骨髓增生异常综合征的患者报告结局工具。通过简明疾病认知问卷(B-IPQ)评估疾病认知。我们前瞻性地收集了75例开始新治疗的患者的数据,这些患者在治疗期间未显示出QUALMS评分或B-IPQ评分有显著变化。B-IPQ评估的八项内容中有六项与QUALMS评分显著相关。在这个小样本中,低危与高危骨髓增生异常综合征患者或其他研究变量(如目标血红蛋白与QUALMS评分无相关性)之间的QUALMS评分没有显著差异。在日常实践中,必须关注疾病认知的初始形成,因为它与健康相关生活质量独立相关,且在治疗期间不会改变(临床试验.gov标识符:NCT04053933)。